Dualitas Signs Up to $1B Roche Deal for Bispecific Antibody Discovery
Image
South San Francisco, Calif. – September 19, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.
Dualitas will screen over 300,000 bispecific antibody combinations for Roche
Under the agreement, Dualitas will use its proprietary DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, in what the company describes as one of the largest-scale bispecific discovery efforts undertaken. Roche will take over all subsequent preclinical development, regulatory, manufacturing and commercial activities for candidates that emerge from the collaboration.